This submission to the Senate Community Affairs Reference Committee makes recommendations to improve the access of Indigenous people across Australia to affordable medicines.
The AMA opposes Government decisions to defer listing of medicines on the PBS that have been recommended by the independent Pharmaceutical Benefits Advisory Committee (PBAC). The Government is leaving itself open to accusations of political interference by ignoring the PBAC assessment and pricing process which is fair, equitable, evidence-based and transparent.
The AMA has made a submission to the Podiatry Board of Australia's consultation process on proposed revisions to their prescribing standards for podiatrists. This submission, which is consistent with previous AMA submissions on this issue to the Podiatry Board, highlights the deficiencies in the Guidelines with respect to course content and accreditation, shared care arrangements and expansion of the national drugs list.
The Australian Medical Association (AMA) and the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) strongly disagree with the decision to reschedule Chloramphenicol eye drops from the Schedule 4 listing to a Schedule 3 medication.
Schedule 4 medications are prescribed by registered medical practitioners or endorsed optometrists. Schedule 3 medications are available to the public from a pharmacist without a prescription.
AMA President, Dr Andrew Pesce, said that first-line eye care is the domain of general practitioners and optometrists, who are readily accessible to patients.
“General practitioners have been specifically trained in clinical diagnosis and appropriate drug use,” Dr Pesce said.
AMA President, Dr Andrew Pesce, said today that the AMA is alarmed that elements of the latest Community Pharmacy Agreement indicate a Government policy shift that puts patient safety at risk by undermining the value of a medical diagnosis.
Dr Pesce said that the Government’s decision to allow pharmacists to dispense prescription medications without a prescription is a threat to patient safety by ignoring the skills and expertise of family doctors and the importance of the doctor-patient relationship.
“Current arrangements allow pharmacists to dispense emergency supplies of medications where a patient has inadvertently run out of necessary medication, so there is no reason to introduce these changes on the basis of patient safety,” Dr Pesce said.
“There has been no consultation with the AMA and the medical profession over this decision, which sends a dangerous signal to patients about access to prescription medicines.”
Draft proposals by the Productivity Commission designed to reduce the
red tape burden on medical practices will benefit patients, the AMA
said today.
A Productivity Commission draft review into regulatory burdens on
business recommends that the Government drop the requirement for
doctors to seek approval from Medicare Australia to prescribe certain
drugs under the Pharmaceutical Benefits Scheme.
AMA Vice President, Dr Steve Hambleton said: “red tape restricts
patient access to medical care and some GPs spend up to nine hours a
week completing paperwork. ”
“Every hour a GP spends doing paperwork, around four patients are denied access to a doctor.”
The AMA Position Statement on Electronic Prescription Transfer Systems – 2009 supports the development of an electronic prescription transfer system as a fundamental building block for a broader eHealth system in Australia. It sets out the high level principles that should underpin an electronic prescription transfer system.
The development of an e system in Australia is supported by:
The AMA position on other aspects of eHealth are set out in the following position statements:
AMA Position Statement – Unique Healthcare Identifiers – 2008
AMA Position Statement – Connectivity – 2007
AMA Position Statement – Safety and Quality of E-Health Systems – 2006
AMA Position Statement: Medicines - 2008